Clinical Trial Update: Lifei Xiaoji Wan Treatment's of Early-stage NSCLC and Its Impact on the Tumor Microenvironment [NA]

View source ↗

Summary

The document discusses a clinical trial evaluating Lifei Xiaoji Wan for early-stage non-small cell lung cancer (lung adenocarcinoma) and its impact on the tumor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lifei Xiaoji Wan (Lifei Xiaoji Wan)

Snippet

Sponsor: Henan University of Traditional Chinese Medicine | Conditions: Early Stage Lung Adenocarcinoma | NA | Status: RECRUITING